ERBB2 and colonic neoplasm: On the contrary, HER2-amplified colon cancer cells were resistant to all anti-EGFR inhibitors, expanding and confirming the results from previous studies regarding the role of HER2 amplification in either primary and acquired resistance to EGFR targeted therapies [17, 34, 35].